Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,620 matching trials from the live ClinicalTrials.gov search.
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Vision Research Foundation
Other
Eligibility
30 Weeks to 36 Weeks
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 14 more
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
96
States / cities
Beverly Hills, California • Campbell, California • Fresno, California + 86 more
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy Product-MCO-010, Sham Injection
Biological · Procedure
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Conditions
Eye Injuries
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab (Lucentis), Argon Laser
Drug · Procedure
Lead sponsor
Rocky Mountain Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed No phase listed Observational Accepts healthy volunteers

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

NCT05107882
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
Interventions
Not listed
Lead sponsor
Optina Diagnostics Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Las Vegas, Nevada • Norfolk, Virginia + 1 more
Conditions
Low Vision
Interventions
Virtual bioptic magnification with large field of view, Full field magnification with small field of view
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 100 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Age Related Macular Degeneration
Interventions
Self management program 'Living with Vision Loss'
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
55 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Age-related Wet Macular Degeneration
Interventions
CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]
Drug
Lead sponsor
Caregen Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more
Conditions
Diabetic Retinopathy (DR)
Interventions
SaMD intended for the detection of diabetic retinopathy in adults with diabetes., An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.
Device
Lead sponsor
Digital Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers

NCT02033668
Conditions
Atrophy, Geographic
Interventions
GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Spinal Cord Injury, Spinal Cord Involvement, Spina Bifida, Transverse Myelitis, Polio and Post-polio Syndrome, Syringomyelia, Spinal Stenosis, Spinal Neoplasms, Spinal Cord Diseases
Interventions
SCI Hard
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 29 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence

NCT06721351
Conditions
Diabetic Retinopathy (DR)
Interventions
Diabetic Retinopathy screening Point of Care Artificial Intelligence
Diagnostic Test
Lead sponsor
Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health
Other
Eligibility
22 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Chula Vista, California • San Diego, California
Enrolling by invitation No phase listed Observational

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

NCT07660640
Conditions
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Interventions
observational study, VOY-101
Other · Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
Completed No phase listed Observational

Diabetes PRP and OCT

NCT01928550
Conditions
Proliferative Diabetic Retinopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
Interventions
Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%
Drug · Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Weeks to 27 Weeks
Enrollment
1,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more
Terminated Phase 2 Interventional Results available

Finasteride for Chronic Central Serous Chorioretinopathy

NCT01585441
Conditions
Retinal Disease
Interventions
Finasteride, Placebo
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Usher's Syndrome
Interventions
Blood draw for the laboratory assessment
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment of AI Program 'DRISTi' as a Screening Tool

NCT07222293
Conditions
Diabetic Retinopathy (DR)
Interventions
Fundus Image Grading
Diagnostic Test
Lead sponsor
Artelus AI
Industry
Eligibility
21 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Oxford, North Carolina • Raleigh, North Carolina
Conditions
Diabetic Macular Edema, Age-related Macular Degeneration
Interventions
MTP-131
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy Volunteer, Retinal Disease, Inherited Retinal Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
5 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Retinitis Pigmentosa
Interventions
Intravitreal autologous CD34+ cells
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Conditions
Diabetes Mellitus, Macular Edema
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland